iBio, Inc. (NYSE AMEX: IBIO)
today announced release of results from a series of scientific studies of the breadth of product applicability of its iBioLaunch™ technology. The results were published in a supplemental edition of the scientific journal
. The peer-reviewed scientific manuscripts describe both vaccine applications and monoclonal antibody applications of iBio’s proprietary plant-based protein expression technology.
“iBio’s platform-as-product business strategy is based on a substantial body of peer-reviewed scientific evidence that the iBio technology offers unique commercial advantages over conventional approaches for the development and manufacture of vaccines and therapeutic proteins,” said Robert Erwin, iBio’s President. “These newly published data reflect pre-clinical work completed by our research collaborator, Fraunhofer USA Center for Molecular Biotechnology, more than a year ago that formed the basis for our current clinical trials and ongoing examination of the limits, if any, of our technology for the commercial expression of proteins for vaccines and biotherapeutics.”
iBioLaunch technology has been employed to make vaccines against pandemic H1N1 influenza and avian influenza H5N1 for two ongoing Phase I human clinical trials. One of the newly published papers describes these experimental vaccines and reports their induction of protective immunity in animal models of influenza. Additional papers report the use of iBioLaunch technology for a novel vaccine for malaria and for production of a proprietary monoclonal antibody that offers protection in animal models of anthrax. Links to abstracts of the publications are provided below:
Plant-based rapid production of recombinant subunit hemagglutinin vaccines targeting H1N1 and H5N1 influenza
Yoko Shoji, Jessica A. Chichester, Mark Jones, Slobodanka D. Manceva, Emily Damon, Vadim Mett, Konstantin Musiychuk, Hong Bi, Christine Farrance, Moneim Shamloul, Natasha Kushnir, Satish Sharma and Vidadi Yusibov, Pages 41 – 50)
A non-glycosylated, plant-produced human monoclonal antibody against anthrax protective antigen protects mice and non-human primates from B. anthracis spore challenge
Vadim Mett, Jessica A. Chichester, Michelle L. Stewart, Konstantin Musiychuk, Hong Bi, Carolyn J. Reifsnyder, Anna K. Hull, Mark T. Albrecht, Stanley Goldman, Les W. J. Baillie and Vidadi Yusibov, Pages 183 – 190
Antibodies to plant-produced Plasmodium falciparum sexual stage protein Pfs25 exhibit transmission blocking activity
Christine E. Farrance, Jessica A. Chichester, Konstantin Musiychuk, Moneim Shamloul, Amy Rhee, Slobodanka D. Manceva, R. Mark Jones, Tarlan Mamedov, Satish Sharma, Vadim Mett, Stephen J. Streatfield, Will Roeffen, Marga van de Vegte-Bolmer, Robert W. Sauerwein, Yimin Wu, Olga Muratova, Louis Miller, Patrick Duffy, Robert Sinden and Vidadi Yusibov, Pages 191 – 198
About iBio, Inc.
iBio, Inc. is a biotechnology company offering its proprietary, transformative iBioLaunch technology platform for the production of biologics including therapeutic proteins and vaccines. The iBioLaunch platform uses transient gene expression in green plants for superior efficiency in protein production. Advantages include significantly lower capital and process costs, and the technology is ideally suited for complex proteins and for applications where speed, scalability, and surge capacity are important. The iBioLaunch technology was developed for iBio by the not-for-profit Fraunhofer USA Center for Molecular Biotechnology (FCMB) during the past eight years to overcome the inadequacies of existing technologies. iBio owns the intellectual property and technology developed at FCMB, and continues to sponsor development and application of the technology for biological applications in human health. Further information is available at
About Fraunhofer USA Center for Molecular Biotechnology
Fraunhofer USA CMB, a division of Fraunhofer USA, Inc., is a not-for-profit research organization whose mission is to develop safe and effective vaccines targeting infectious diseases and autoimmune disorders. The technology CMB developed for iBio, Inc. provides a safe, rapid and economical alternative for both vaccine and therapeutic protein production. The Center conducts research in the area of plant biotechnology, utilizing new, cutting edge technologies applicable to the diagnosis, prevention and treatment of human and animal diseases. The Center houses individuals with expertise and excellence in plant virology, pathology, molecular biology, immunology, vaccinology, protein engineering, and biochemistry. Further information is available at
Statements included in this news release related to iBio, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the Company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects. Further information on potential risk factors that could affect the Company's financial results can be found in the company's Reports filed with the Securities and Exchange Commission.